Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A magnetic resonance imaging study to assess the short-term physical modifications of the disease process after SB-061 treatment

Trial Profile

A magnetic resonance imaging study to assess the short-term physical modifications of the disease process after SB-061 treatment

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SB 061 (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms MODIFY-MRI
  • Most Recent Events

    • 25 Apr 2019 According to a Symic Bio media release, the latest financing will be utilized to advance Symic Bios disease-modifying osteoarthritis drug, SB-061, into this global phase 2b trial which is expected to be started in the latter half of 2019.
    • 27 Aug 2017 New trial record
    • 23 Aug 2017 According to a SYMIC Biomedical media release, the company expects to report top-line results from the study in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top